←Tourette Syndrome
Study register · detail Fallserie · Tourette Syndrome · 2017

Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients.

Jakubovski et al. ·International journal of molecular sciences Impact 5.8
Clear benefit GRADE Very low 36 citations
Samplen = 2 Pat.
Durationunclear
EndpointVocal blocking tics
Blindingn.a.
DesignFallserie
Key finding

Cannabis-based medications led to significant improvement of vocal blocking tics and comorbid conditions in both patients.

Summary

Two young patients with treatment-refractory Tourette syndrome and severe vocal blocking tics; Case 1 (19 years): cannabis 0,1 g/day; Case 2 (16 years): dronabinol up to 33,6 mg/day. Both showed significant improvement of vocal blocking tics and comorbidities with good tolerability.

P
PopulationTwo adolescent male patients (19 and 16 years) with treatment-resistant Gilles de la Tourette syndrome and severe vocal blocking tics as well as palilalia
I
InterventionCase 1: Medical cannabis 0,1 g/day inhaled; Case 2: Dronabinol maximum 22,4–33,6 mg/day oral
O
OutcomeSignificant improvement of vocal blocking tics as well as comorbid symptoms in both patients; good tolerability
Confidence in the evidence
Very low

The lowest GRADE level, the effect estimate remains uncertain.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding —
Effect size Clear benefit
Citations / year ★★★★★
Authors
Jakubovski E, Muller-Vahl K
DOI 10.3390/ijms18081739↗
Design: Fallserie
Share
Abstract
We report the cases of two young German male patients with treatment-resistant Tourette syndrome (TS), who suffer from incapacitating stuttering-like speech disfluencies caused by vocal blocking tics and palilalia. Case 1: a 19-year old patient received medical cannabis at a dose of 1 x 0.1 g cannabis daily. Case 2: a 16-year old patient initially received dronabinol at a maximum dose of 22.4-33.6 mg daily. Both treatments provided significant symptom improvement of vocal blocking tics as well as of comorbid conditions and were well tolerated. Thus, cannabis-based medicine appears to be effective in treatment-resistant TS patients with vocal blocking tics.
Indication
Further studies on Tourette Syndrome
All studies →
S Koppel et al. · 2014 · Neurology
545 citations
Systematic review: Efficacy and safety of medical Cannabis in selected neurologic disorders [RETIRED]
Mixed Systematische Review

AAN-Leitlinie (Guideline Development Subcommittee) — Systematische Review über k=34 Studien (davon 8 Class I) zu medizinischem Cannabis bei neurologischen Erkrankungen. Für Tourette-Syndrom: orale Cannabinoide von unbekannter Wirksamkeit (insufficient evidence). Risiko schwerer psychopathologischer Nebenwirkungen ~1%. [RETIRED-Status]

10.1212/wnl.0000000000000363 View study →
S Pringsheim et al. · 2019 · Neurology
249 citations
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.
Clear benefit Systematic Review

American Academy of Neurology Leitlinie basierend auf systematischer Review zu Tic-Behandlung bei Tourette-Syndrom. Hohe Konfidenz für Comprehensive Behavioral Intervention for Tics vs. Psychoedukation. Moderate Konfidenz für Haloperidol, Risperidon, Aripiprazol, Tiaprid, Clonidin, OnabotulinumtoxinA, 5-ling granule, Ningdong granule und Tiefenhirnstimulation des Globus pallidus zur Tic-Reduktion vs. Placebo. Niedrige Konfidenz (möglicherweise wirksam) für Pimozid, Ziprasidon, Metoclopramid, Guanfacin, Topiramat und Tetrahydrocannabinol. Evidenz für verschiedene Nebenwirkungen (Gewichtszunahme, medikamenteninduzierte Bewegungsstörungen, erhöhte Prolaktinspiegel, Sedierung, kardiovaskuläre Effekte).

10.1212/wnl.0000000000007467 View study →
A Rice et al. · 2024 · European child & adolescent psychiatry
24 citations
Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.
No benefit demonstrated Systematic Review

Systematische Review zu Cannabinoiden bei neuro­psychiatrischen und neuro­entwicklungs­bedingten Störungen bei Kindern/Jugendlichen (≤18 Jahre); k=18 eingeschlossene Artikel zu 8 Störungsbildern, davon n=3 zu Tourette-Syndrom. Nur 1 RCT identifiziert; Rest: 1 Open-Label-Studie, 3 unkontrollierte Vorher-Nachher-Studien, 2 Fallserien, 11 Fallberichte — hohes Bias-Risiko. Schlussfolgerung: limitierte und generell schlechte Evidenzqualität für Cannabinoid-Wirksamkeit.

10.1007/s00787-023-02169-w View study →

The impediment to action advances action. — Marcus Aurelius